Drugs / sodium dimethylbutyrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00842088 | Mar 2009 → Jul 2010 | sickle cell disease | HemaQuest Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium dimethylbutyrate | “Accordingly, sodium dimethylbutyrate (HQK-1001), an orally-bioavailable, promoter-targeted fetal globin gene-inducing agent, was evaluated in a randomized, blinded,...” PMID 22887019 ↗ Aug 2012 |
| Known as | HQK-1001 | “Accordingly, sodium dimethylbutyrate (HQK-1001), an orally-bioavailable, promoter-targeted fetal globin gene-inducing agent, was evaluated in a randomized, blinded,...” PMID 22887019 ↗ Aug 2012 |